Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Update

Quantum Biopharma Ltd. (NASDAQ:QNTM) saw a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 76,665 shares, an increase of 63.2% from the January 15th total of 46,986 shares. Based on an average daily volume of 65,698 shares, the short-interest ratio is presently 1.2 days. Currently, 2.2% of the shares of the company are sold short. Currently, 2.2% of the shares of the company are sold short. Based on an average daily volume of 65,698 shares, the short-interest ratio is presently 1.2 days.

Institutional Investors Weigh In On Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Steward Partners Investment Advisory LLC bought a new position in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned approximately 0.11% of Quantum Biopharma as of its most recent SEC filing. 1.24% of the stock is currently owned by hedge funds and other institutional investors.

Quantum Biopharma Trading Down 0.3%

Shares of NASDAQ:QNTM opened at $3.64 on Friday. Quantum Biopharma has a 12 month low of $3.62 and a 12 month high of $38.25. The stock has a market cap of $13.89 million, a P/E ratio of -0.33 and a beta of 0.30. The company has a 50 day moving average of $6.88 and a 200 day moving average of $12.41.

Analyst Ratings Changes

A number of research firms recently weighed in on QNTM. Wall Street Zen lowered shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum Biopharma in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.